Causes and outcome of hospitalisations in Tunisian patients with systemic lupus erythematosus

M Jallouli,1 H Hriz,1 Y Cherif,1 S Marzouk,1 M Snoonssi,1 F Frikha,1 R Ben Salah,1 H Masmoudi,2 Z Bahloul1

ABSTRACT
Objective: To describe the most common reasons of admission of Tunisian patients with systemic lupus erythematosus (SLE) and the outcomes of these hospitalisations.

Method: The charts of patients with SLE who were hospitalised at our Department of Internal Medicine during a 2-year period from January 2011 to December 2012 were retrospectively reviewed, and the demographic characteristics, clinical and laboratory features, as well as all comorbidities, were collected.

Results: There were 128 episodes of hospitalisation of 87 patients with SLE. 25 patients (28.7%) were admitted twice or more. The median length of stay for all admissions was 11 days (2–76). The total number of days of hospitalisation was 1896 days, which represent 10.7% of the total number of days of hospitalisation in our department. The most common overall reason for hospitalisation was active SLE (55 events, 43%). In 29 patients, SLE was newly diagnosed during hospitalisation. Other causes of hospitalisation included assessment of the disease, infections (9.4%) and associated autoimmune disease (6.25%). Adverse drug reaction (3.1%) and thromboembolic events (1.25%) were uncommon causes of hospitalisations. There was a significant difference in length of stay between patients admitted with SLE flare and those admitted for non-SLE flare reasons (p<0.01). Four hospitalisations (3%) resulted in death. The principal cause of death was active SLE.

Conclusions: Hospitalisation of patients with SLE is common in our department. Our study of this North African SLE population confirms the findings of previous studies suggesting that active SLE and infection remain the most common causes of hospitalisation of patients with SLE.

INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown aetiology with a broad spectrum of clinical and immunological manifestations. This chronic disease is difficult to diagnose and treat, and patients with SLE may require frequent hospitalisations. Few studies on hospitalisation of patients with SLE have been reported earlier.1–6 These studies have involved North Americans,2 3 Asians1 but not North Africans.

The objective of this study was to describe the most common reasons of admission and the outcomes of patients with SLE in Tunisia.
±11.5 years at diagnosis and 35.3±12.8 years at admission. The median disease duration between diagnosis and hospitalisation was 26 months (0–288 months).

During this study, there were 128 hospitalisation events, which represent 5.95% of all admissions in our department. Twenty-five patients (28.7%) were admitted twice or more.

Table 1 lists all the discharge diagnoses in patients with SLE. The most common overall reason for hospitalisation was active SLE (55 events, 43%). In 29 patients, SLE was newly diagnosed during hospitalisation. The other 26 patients experienced a flare after a median time of 42 months (2–140). Patients hospitalised for SLE disease flare compared with other causes were younger (32 vs 37.8 years; p<0.001) and had a shorter disease course (42 (2–140) vs 57 (1–288) months; p=0.04). Among the individuals admitted with active disease, cutaneous and haematological manifestations were the most common (table 1). Seventeen patients (30.9%) had active lupus nephritis.

Acute infections were responsible for 9.4% of admissions. The majority of infections was bacterial and included pulmonary (five cases), urinary tract (two cases) and cutaneous (two cases) infections. There were two cases of salmonella arthritis and one case of brucellosis.

The diagnosis of an associated autoimmune disease accounted for 6.25% of admissions. They included inflammatory myositis (four cases), autoimmune thyroiditis (one case), autoimmune hepatitis (one case) and pernicious anaemia (one case). Adverse drug reaction (3.1%) and thromboembolic events (1.25%) were uncommon causes of hospitalisations.

The median length of stay for all admissions was 11 days with a range from 2 to 76 days. The total number of days of hospitalisation of patients with SLE was 1896 days, which represent 10.7% of the total number of days of hospitalisation in our department. There was a significant difference in length of stay between patients admitted with SLE flare and those admitted for non-SLE flare reasons (18 (2–70) vs 8 (2–76) days; p<0.01).

Among 128 hospitalisations, 4 (3%) resulted in death (table 2). All patients were initially hospitalised for severe active SLE. During their hospitalisation, one patient had also pneumonia and the other a perirenal haematoma secondary to a renal biopsy.

## DISCUSSION

In this retrospective series, we describe the most common reasons of admission and the outcomes of hospitalisation. The most common overall reason for hospitalisation was active SLE (55 events, 43%). In 29 patients, SLE was newly diagnosed during hospitalisation. The other 26 patients experienced a flare after a median time of 42 months (2–140). Patients hospitalised for SLE disease flare compared with other causes were younger (32 vs 37.8 years; p<0.001) and had a shorter disease course (42 (2–140) vs 57 (1–288) months; p=0.04). Among the individuals admitted with active disease, cutaneous and haematological manifestations were the most common (table 1). Seventeen patients (30.9%) had active lupus nephritis.

Acute infections were responsible for 9.4% of admissions. The majority of infections was bacterial and included pulmonary (five cases), urinary tract (two cases) and cutaneous (two cases) infections. There were two cases of salmonella arthritis and one case of brucellosis.

The diagnosis of an associated autoimmune disease accounted for 6.25% of admissions. They included inflammatory myositis (four cases), autoimmune thyroiditis (one case), autoimmune hepatitis (one case) and pernicious anaemia (one case). Adverse drug reaction (3.1%) and thromboembolic events (1.25%) were uncommon causes of hospitalisations.

The median length of stay for all admissions was 11 days with a range from 2 to 76 days. The total number of days of hospitalisation of patients with SLE was 1896 days, which represent 10.7% of the total number of days of hospitalisation in our department. There was a significant difference in length of stay between patients admitted with SLE flare and those admitted for non-SLE flare reasons (18 (2–70) vs 8 (2–76) days; p<0.01).

Among 128 hospitalisations, 4 (3%) resulted in death (table 2). All patients were initially hospitalised for severe active SLE. During their hospitalisation, one patient had also pneumonia and the other a perirenal haematoma secondary to a renal biopsy.

## DISCUSSION

In this retrospective series, we describe the most common reasons of admission and the outcomes of hospitalisation. The most common overall reason for hospitalisation was active SLE (55 events, 43%). In 29 patients, SLE was newly diagnosed during hospitalisation. The other 26 patients experienced a flare after a median time of 42 months (2–140). Patients hospitalised for SLE disease flare compared with other causes were younger (32 vs 37.8 years; p<0.001) and had a shorter disease course (42 (2–140) vs 57 (1–288) months; p=0.04). Among the individuals admitted with active disease, cutaneous and haematological manifestations were the most common (table 1). Seventeen patients (30.9%) had active lupus nephritis.

Acute infections were responsible for 9.4% of admissions. The majority of infections was bacterial and included pulmonary (five cases), urinary tract (two cases) and cutaneous (two cases) infections. There were two cases of salmonella arthritis and one case of brucellosis.

The diagnosis of an associated autoimmune disease accounted for 6.25% of admissions. They included inflammatory myositis (four cases), autoimmune thyroiditis (one case), autoimmune hepatitis (one case) and pernicious anaemia (one case). Adverse drug reaction (3.1%) and thromboembolic events (1.25%) were uncommon causes of hospitalisations.

The median length of stay for all admissions was 11 days with a range from 2 to 76 days. The total number of days of hospitalisation of patients with SLE was 1896 days, which represent 10.7% of the total number of days of hospitalisation in our department. There was a significant difference in length of stay between patients admitted with SLE flare and those admitted for non-SLE flare reasons (18 (2–70) vs 8 (2–76) days; p<0.01).

Among 128 hospitalisations, 4 (3%) resulted in death (table 2). All patients were initially hospitalised for severe active SLE. During their hospitalisation, one patient had also pneumonia and the other a perirenal haematoma secondary to a renal biopsy.

## DISCUSSION

In this retrospective series, we describe the most common reasons of admission and the outcomes of hospitalisation. The most common overall reason for hospitalisation was active SLE (55 events, 43%). In 29 patients, SLE was newly diagnosed during hospitalisation. The other 26 patients experienced a flare after a median time of 42 months (2–140). Patients hospitalised for SLE disease flare compared with other causes were younger (32 vs 37.8 years; p<0.001) and had a shorter disease course (42 (2–140) vs 57 (1–288) months; p=0.04). Among the individuals admitted with active disease, cutaneous and haematological manifestations were the most common (table 1). Seventeen patients (30.9%) had active lupus nephritis.

Acute infections were responsible for 9.4% of admissions. The majority of infections was bacterial and included pulmonary (five cases), urinary tract (two cases) and cutaneous (two cases) infections. There were two cases of salmonella arthritis and one case of brucellosis.

The diagnosis of an associated autoimmune disease accounted for 6.25% of admissions. They included inflammatory myositis (four cases), autoimmune thyroiditis (one case), systemic sclerosis (one case), autoimmune hepatitis (one case) and pernicious anaemia (one case). Adverse drug reaction (3.1%) and thromboembolic events (1.25%) were uncommon causes of hospitalisations.

The median length of stay for all admissions was 11 days with a range from 2 to 76 days. The total number of days of hospitalisation of patients with SLE was 1896 days, which represent 10.7% of the total number of days of hospitalisation in our department. There was a significant difference in length of stay between patients admitted with SLE flare and those admitted for non-SLE flare reasons (18 (2–70) vs 8 (2–76) days; p<0.01).

Among 128 hospitalisations, 4 (3%) resulted in death (table 2). All patients were initially hospitalised for severe active SLE. During their hospitalisation, one patient had also pneumonia and the other a perirenal haematoma secondary to a renal biopsy.
patients with SLE in Tunisia. Few studies on hospitalisation of patients with SLE have been reported earlier.\textsuperscript{1–6} These studies have involved North Americans,\textsuperscript{2,3} Asians\textsuperscript{1} but not North Africans.

We found that SLE was responsible for 5.95% of all admissions in our department. These findings point out that although SLE is a rare condition, the number of patients with SLE is not trivial. Patients with SLE had also a high healthcare use\textsuperscript{8} since they were responsible for 10.7% of the total number of days of hospitalisation.

In our study, active SLE was the most common reason for hospitalisation of patients with SLE (43%). This is consistent with the results reported in the literature.\textsuperscript{1–3} The rate of admissions for this cause is higher than that reported in Northern America (17.5–35%)\textsuperscript{2,3} but lower when compared with Asian populations (58%).\textsuperscript{1} These discrepancies may be due to ethnic and socioeconomic characteristics and to differences in healthcare systems. The patients hospitalised for SLE disease flare compared with other causes had a shorter disease course, like other series.\textsuperscript{3,8} These findings are expected since it is well known that SLE is mainly active in the first 5 years of disease progression.

The second most common reason for hospitalisation of our patients with SLE was disease’s assessment (26.5%). Our department is a tertiary referral centre for the treatment of patients with SLE and most of our patients come from across southern Tunisia. Thereby, this high rate might be explained by a strategy of our medical team to overcome difficulties of healthcare access as many of our patients live in remote areas.

Despite the great improvement in the management of SLE, infection remains an important cause of morbidity and mortality in patients with SLE. As seen in literature,\textsuperscript{1–3} acute infections were one of the leading causes of hospitalisations in our study and accounted for 9.4% of admissions.

It is common that SLE aggregates with other autoimmune diseases. The study of Chambers et al.\textsuperscript{40} suggests that up to a third of lupus patients might develop another autoimmune disease and that the prevalence of some of them (Sjogren’s syndrome, Hashimoto’s hypothyroidism, myositis, antiphospholipid syndrome, etc) could be higher than in the general population. The present study emphasises that there is a high prevalence of polyautoimmunity in patients with SLE since it represents the fourth most common reason for hospitalisation of patients with SLE (6.25%).

Interestingly, there was no hospitalisation due to coronary artery disease during our study. In an earlier report,\textsuperscript{11} we found that no patient died of cardiovascular event. While coronary artery disease is firmly established as a major cause of mortality and morbidity in other ethnic groups,\textsuperscript{6,12,13} it remains a less frequent cause of hospitalisation in our population. These findings are comparable to those seen in Chinese\textsuperscript{1} and South Koreans.\textsuperscript{14}

In conclusion, hospitalisation of patients with SLE is common in our department and can be prolonged. Our study of this North African SLE population confirms the findings of previous studies suggesting that active SLE and infection remain the most common causes of hospitalisation of patients with SLE.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES


Causes and outcome of hospitalisations in Tunisian patients with systemic lupus erythematosus

M Jallouli, H Hriz, Y Cherif, S Marzouk, M Snoussi, F Frikha, R Ben Salah, H Masmoudi and Z Bahloul

Lupus Sci Med 2014 1:
doi: 10.1136/lupus-2014-000017

Updated information and services can be found at:
http://lupus.bmj.com/content/1/1/e000017

These include:
References
This article cites 14 articles, 4 of which you can access for free at:
http://lupus.bmj.com/content/1/1/e000017#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Epidemiology and Outcomes (28)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/